INTRODUCTION
Frontotemporal degeneration (FTD) is an umbrella term for a spectrum of clinically, genetically and pathologically heterogeneous neurodegenerative disorders. Major FTD clinical phenotypes include: behavioral variant frontotemporal dementia (bvFTD) , nonfluent and semantic variants of primary progressive aphasia (PPA) , progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS) (Mathew et al., 2012) . Frontotemporal lobar degeneration with TAR DNA-binding protein TDP-43 inclusions (FTLD-TDP) is the major pathological subtype accounting for 50% of cases (Mackenzie and Neumann, 2016) . Familial forms of FTLD-TDP are mostly related to GRN gene mutations and C9orf72 repeat expansion (Mackenzie and Neumann, 2016) .
GRN loss-of-function mutations are among the most frequent genetic causes, responsible for 20% of familial FTD. So far, more than 100 deleterious GRN mutations have been identified (http://www.molgen.ua.ac.be) (Cruts et al., 2012; Moore et al., 2020) , most leading to progranulin haploinsufficiency (Baker et al., 2006; Cruts et al., 2006; Moore et al., 2020) .
Progranulin is a ubiquitous protein involved in several biological pathways including development, neuroinflammation, tumorigenesis, degradation-lysosomal pathway and neuronal survival (Cenik et al., 2012) . It is secreted in biological fluids and can be measured in patient's plasma and cerebrospinal fluid (CSF). Plasma progranulin level was identified as an efficient marker for predicting GRN gene mutations (Ghidoni et al., 2008; Meeter et al., 2016) and deletions when decreased or undetectable (Calvi et al., 2015; Clot et al., 2014; Galimberti et al., 2018b) . Previous studies also demonstrated the reliability of reduced plasma progranulin level in asymptomatic relatives carrying GRN mutations (Finch et al., 2009; Galimberti et al., 2018b) , which strengthened the interest for this biomarker as a tool for monitoring therapeutic trials based on enhancing progranulin levels approaches (Galimberti et al., 2018a) . However, how plasma progranulin levels evolve during disease progression in GRN carriers is still unknown and studies assessing the longitudinal trajectory of progranulin in plasma over time are lacking.
GRN mutations are associated with a wide range of age at onset (AAO), from the 40s to over 80s, and produce a variable clinical spectrum dominated by bvFTD before PPA and CBS (Le Ber et al., 2008) (Moore et al., 2020) . Accumulating evidence suggested that genetic modifiers such as transmembrane protein 106 B (TMEM106B) single nucleotide polymorphisms could modulate progranulin expression, and, notably, the minor G-allele of rs1990622 was established as protective in homozygous state (Cruchaga et al., 2011; Finch et al., 2011; Van Deerlin et al., 2010) . However, mechanisms underlying the phenotypic variability in GRN carriers are still largely unknown and biological factors predicting disease heterogeneity remain to be identified.
Predicting AAO and clinical phenotypes of GRN carriers is a major issue for genetic counseling, to deliver accurate information to presymptomatic carriers, and in perspective of upcoming therapeutic trials. In this study, we aimed to assess whether progranulin expression in plasma could be used as a biological marker to predict the AAO, clinical phenotype, disease progression and evaluated the longitudinal trajectory of plasma progranulin levels over time in a large population of 160 GRN mutation carriers. We also evaluated how plasma progranulin physiologically evolve with aging in controls, and determined analytical performances of the test, in order to optimize and generalize its use in clinical practice.
MATERIAL AND METHODS

Subjects' selection
Our study population consisted of FTD patients with GRN gene mutations, presymptomatic GRN mutation carriers, and controls negative for GRN mutations. FTD patients have been recruited in a tertiary memory clinic (Institut de la Mémoire et de la Maladie d'Alzheimer, IM2A, Pitié Salpêtrière hospital, Paris, France) and through a national network of expert centers on FTLD/FTLD-ALS (Inserm RBM 02-059). Their biological samples and clinical data have been collected since 1998, as described previously (Le Ber et al., 2006 ). Between 1998 and 2019 patients carrying GRN mutations were identified by these centers. Their genetic status was established as previously described (Le Ber et al., 2008) . All participants signed an informed consent for clinical genetic study approved by local ethical committee.
Plasma progranulin dosage is routinely used in clinical practice in France, since 2009 by all the French network's centers. Amongst the 191 GRN carriers, 129 were recruited during the ten-year period between 2009 and 2019, and therefore had undergone plasma progranulin measurement. Those 129 patients (109 probands, 20 relatives) were included in this study.
They consisted in 85 patients with bvFTD, 31 PPA, 11 CBS and 2 patients with rare clinical presentations mimicking dementia with Lewy bodies (DLB) and posterior cortical atrophy (PCA). Additionally, plasma progranulin has been measured in 31 presymptomatic GRN mutation carriers described elsewhere (Caroppo et al., 2015) , which were included in the current study. All GRN carriers were European (mostly French) except seven African patients.
Most had frameshift (n=74), nonsense (n=55), splice-site mutations (n=24) or exonic deletions (n=3) (see supplementary table 1). Two carried the c.1A>G, p.M1? mutation and two had the c.19T>C, p.Trp7Arg mutation in the signal peptide (Saracino et al., 2019) . The list of mutations is provided in Supplementary Table 1 . Our control group (n=133) consisted of healthy controls (HC, n=71) and FTD patients carrying C9orf72 repeat expansion (FTD-C9orf72, n=62), all negative for GRN mutations.
Longitudinal plasma samples were available in a subset of 112 individuals (73/129 GRN carriers and 39/133 controls) with a mean follow-up period between the first and the second sample of 12.7±11.8 months; fewer individuals had more than two samples over time (see Supplementary Table 2 ). Among them, 32 (15 GRN carriers and 17 controls) had a remarkably long follow-up period, close to four years between the first and the last plasma progranulin measure.
Laboratory methods
Plasma progranulin dosage, precision and coefficient of variation of the ELISA method
Overall, we analyzed progranulin levels in a total of 458 plasma samples, consisting of 270 baseline and follow-up samples of patients and presymptomatic GRN carriers, as well as of 188 samples of GRN-negative controls ( Supplementary Table 2 ). Blood samples have been collected on EDTA using the same protocol for all participants. All samples have been centralized in the Pitié-Salpêtrière laboratory. EDTA samples were centrifuged at 3500 rpm for 20 minutes at + 4°C, were aliquoted by fraction of 500 µL and then frozen in polypropylene tubes at -80°C until assay. Plasma measurements were performed using standardized procedure, blinded to mutation status. Progranulin levels were measured using the enzyme-linked immunosorbent assay (ELISA) with the progranulin-human-Elisa kit (Adipogen, Coger SAS, France), according to manufacturer's instructions.
Preliminarily to any analysis, we evaluated the coefficient of variation (CV%) within an assay (intra-assay variability or within-run precision) by analyzing the same control sample on 10 plates in the same run (mean concentration 146.2 ng/mL), and between assays precision (inter-assay variability) by analyzing the same control sample (mean concentration 167.4 ng/mL) on ten different experiments on independent batches. Median intra-assay coefficient of variation was 7.6% and inter-assay variability was 9.5%. A cut-off of 15% was considered acceptable for CV%. All the plasma samples were analyzed in duplicates, and progranulin measurement was repeated when CV% between duplicates was higher than 15%.
TMEM106B rs1990622 genotyping
We studied whether A or G alleles of rs1990622, a single nucleotide polymorphism (SNP) of TMEM106B gene, influence plasma progranulin levels or age at onset. The SNP rs1990622 was genotyped on DNA extracted from blood lymphocytes of 66 European GRN carriers (41 patients, 25 presymptomatic carriers) included in this study using the Sanger method, as previously described (Lattante et al., 2014) .
Statistical analysis
We used the coefficient of variation (CV%) to evaluate intra-individual variability of plasma progranulin levels, defined as two different samples from the same individual obtained over a time span, in 39 GRN-negative controls. Receiver-Operating characteristic (ROC) curve and Youden index were used to determine the optimal cut-off value, sensitivity (Se) and specificity (Sp) of progranulin in plasma in the studied population.
We compared plasma progranulin levels in participants according to gender, AAO, phenotype (bvFTD or PPA or CBS), GRN mutation characteristics (nonsense, frameshift or splice site mutation; exonic localization), and TMEM106B SNP. The continuous variables were tested for normality of distribution with Shapiro-Wilk test. Demographic characteristics, plasma progranulin levels and genetics (presence of GRN mutations, TMEM106B alleles and genotype frequencies) were compared between participants (GRN patients, GRN presymptomatic carriers and controls) using Chi-squared tests, Student's T test, Wilcoxon-Mann-Whitney test, Kruskal-Wallis test, ANOVA, followed by Bonferroni post-hoc analyses for multiple comparisons. Correlations between plasma progranulin levels and age were calculated with the Spearman's rank coefficient (rS). Linear regression was used to assess the association between TMEM106B, AAO and plasma progranulin levels.
The longitudinal progression rate of plasma progranulin levels was measured using relative annualized changes, to account for different follow-up length since not all participants were assessed at the same time point. Relative annualized progression rates of plasma progranulin levels were calculated as the total change in plasma progranulin standardized by baseline progranulin and divided by the follow-up duration between the two time points. The results are expressed as percentage per year. We separately analyzed data from a subgroup of 32 individuals with the longest follow-up period (>4 years between measures). We used a fitted regression line to assess the relationship between plasma progranulin levels and time from disease onset in GRN mutation carriers. Time from disease onset was calculated using the real AAO for affected GRN carriers, whereas the mean familial AAO was used to estimate time to expected onset in presymptomatic GRN carriers as previously reported (Rohrer et al., 2015) .
Data were analyzed with the statistical software SPSS 25.0 (SPSS Inc., Chicago, IL). A pvalue of 0.05 was set for statistical significance.
RESULTS
Demographic data and plasma progranulin levels of all participants are shown in Table 1 and 
Plasma progranulin levels in controls: variation with age and over time
We have measured plasma progranulin levels in 133 controls consisting of 71 HC and 62 FTD-C9orf72 (Table 1 and 
Plasma progranulin levels in GRN carriers: relation with gender, AAO, phenotype, disease progression and type of GRN mutations
We measured levels of progranulin in plasma from 160 GRN mutation carriers consisting of 129 FTD patients and 31 presymptomatic carriers. Median plasma progranulin levels were 36
[IQR: 29-45.7] ng/mL in the entire GRN carriers group. No difference was found between patients and presymptomatic GRN carriers (p>0.05) (see Table 1 ).
Plasma progranulin levels were significantly decreased in both GRN patients (36) (37) (38) (39) (40) (41) (42) (43) (44) ng/mL) and presymptomatic GRN carriers (40 [IQR: 28-54] ng/mL) with respect to controls (p<0.001) (see Figure 1 ). There was no correlation between plasma progranulin levels and the age at sampling (rS=-0.08, p=0.32). Plasma progranulin levels were significantly 10% lower in males compared to females GRN carriers (p=0.019). No statistically significant differences in plasma progranulin levels were observed according to GRN mutation types or localization (see Table 2 ).
In the group of GRN patients, there was no correlation between plasma progranulin levels and the age at disease onset (rS= 0.028, p=0.75, see Supplementary Figure 2 ). There were no significant differences between the three major FTD phenotypes i.e. bvFTD (n=85 patients), PPA (n=31), and CBS (n=11) (see Table 2 and Supplementary Figure 3) .
The optimal threshold of plasma progranulin levels
The ROC curve analysis showed that plasma progranulin levels significantly discriminated individuals carrying GRN mutations from controls negative for GRN mutations. The area under the curve (AUC) was estimated to be 0.997 (95% confidence interval=0.993-1, p<0.0001) (see Figure 2A ). Figure 2B shows cut-off values and the corresponding sensitivity and specificity. A cut-off of 71 ng/mL yielded the best sensitivity/specificity trade-off: 98.1% and 98.5%, respectively. Diagnostic accuracy was 98.3%.
Considering the gender difference in plasma progranulin levels, we performed distinct ROC curve analyses according to sex, and found that the optimal threshold for females (77 ng/mL, Se=96.4%, Sp=98.5%) was higher than in males (71 ng/mL, Se=100%, Sp=98.5%) (see Supplementary Tables 3 and 4 ).
False-negative results
Levels above the threshold of 71 ng/mL were detected on 5/270 plasmas (1.9%) of GRN carriers analyzed in this study (Supplementary Table 5 ). The five measures above the threshold were provided from 4 different GRN carriers. In two carriers, a second measure on an independent sample turned out to be under the threshold of 71 ng/mL (including one female whose higher level was 77 ng/mL, consistently with the cut-off established for females). Conversely, one male patient, with a family history of FTD, carrying the p.Glu498Aspfs*12 mutation had persistent normal plasma levels (85 ng/mL) at baseline and on a control sample performed 20 months later (103 ng/mL). This FTD patient suffered from morbid obesity and hyperuricemia and was treated by allopurinol and venlafaxine.
Longitudinal study of progranulin levels over time, according to disease stage and disease progression
The regression line to assess the relationship between the time from disease onset and plasma progranulin levels in all the samples obtained from GRN mutation carriers including presymptomatic GRN carriers (mean expected time to onset= -21.1±11.5 years) and affected GRN patients (mean AAO= 59.2±8.0 years, mean disease duration=3.5±3.4 years), showed overall a stability of plasma progranulin values regardless of the clinical status of carriers (see 
Influence of TMEM106B genotype on plasma progranulin level and age at onset
The frequency of minor G-allele was lower in GRN carriers compared to the European population (25% versus 40.8%, respectively) from International genome database (https://www.internationalgenome.org/). The frequency of GG-genotype was also lower in GRN carriers compared to the European population (6.1% versus 15.9%, respectively). Linear regression analyses using gender as covariate showed no significant association of rs1990622 genotypes with AAO (standardized β coefficient=0.11, p=0.49) and plasma progranulin levels (standardized β coefficient=0.2, p=0.095). Nonetheless, GRN carriers homozygous for the minor G-allele had higher plasma progranulin levels (51 [36-64] ng/mL) than ng/mL) and AG carriers (31[24-46] ng/mL), without reaching statistical significance (p=0.13).
DISCUSSION
In this study, we evaluated plasma progranulin levels in 160 GRN mutation carriers consisting of 129 FTD patients and 31 presymptomatic GRN carriers, depicting the largest population analyzed so far. This is also the first longitudinal study evaluating progranulin plasma level changes in both controls and GRN carriers over a long time period (see Table 3 ). Our study provided evidence that plasma progranulin levels in controls did not correlate with age, and varied a little over time with a CV% of 14.7%. We confirmed that plasma progranulin levels are a valid and reliable biological marker for predicting GRN mutation status. This study ascertained that progranulin in plasma has an excellent screening performance, with high sensitivity and specificity for detecting GRN mutation carriers.
Our study estimated the optimal cut-off point to be at 71 ng/mL. There is a discrepancy in optimal cut-off values between studies (Finch et al., 2009; Ghidoni et al., 2012) that alternately established thresholds of 112 ng/mL (Finch et al., 2009) , 74 ng/mL (Ghidoni et al., 2008) or 61.5 ng/mL (Galimberti et al., 2018b; Ghidoni et al., 2012) to discriminate GRN carriers from non-carriers (see Table 3 ). The most recent study suggested a cut-off of 61.5 ng/mL with a high specificity of 99.6% and a lower sensitivity of 95.8% (Ghidoni et al., 2012) . Using a threshold of 61.5 ng/mL, we would have had a sensitivity of 93.8% in our population and have missed the detection of 10/160 (6.2%) GRN carriers. Considering the important clinical implications in routine screening settings, we rather recommend that the choice of the optimal cut-off should be based on the priority of sensitivity over specificity, to minimize false negative errors and not miss potential GRN mutations carriers.
As previously outlined by Nicholson et al.(Nicholson et al., 2014) , plasma progranulin levels were also found to be influenced by sex in our study, with males harboring lower measures than females. We might hypothesize that the interaction of the GRN gene with sex steroids could play a role since it has been showed that GRN gene expression was induced by estrogens (Suzuki et al., 2009) . This led us to stratify ROC curve analyses by gender and propose distinct thresholds, lower in males (71 ng/mL) than in females (77 ng/mL). This observation warrants further research to be confirmed with potentially important implications in clinical practice.
Our results strengthened the notion that plasma progranulin levels are decreased in presymptomatic GRN carriers. In our study, some carriers already showed decreased levels during their 20s, more than four decades before the expected disease onset (Galimberti et al., 2018b) (Figure 3 ). Our results also provided evidence for the stability of levels throughout longitudinal trajectory in GRN carriers. More importantly, this is the first longitudinal study demonstrating the stability of plasma progranulin levels over an extended follow-up period in GRN mutations carriers (>4 years in some carriers). Only one previous study showed stable levels but over a limited one-week period (Meeter et al., 2016) . Our results suggest that plasma progranulin levels remain globally low, at a steady pace, throughout the natural history of disease, ranging from the presymptomatic stage to full-blown FTD, with no association with disease progression. Bringing evidence of the stability of plasma progranulin levels over long time in GRN mutations carriers has critical implications for the monitoring of upcoming clinical trials based on progranulin restoring therapy.
Furthermore, these findings support that plasma progranulin levels are not predictive of AAO or of clinical phenotypes. Importantly, this study is the first to provide evidence for similar levels of progranulin expression in bvFTD, PPA or CBS patients, regardless of their clinical phenotype. This suggest that the phenotypic variability of GRN carriers is not driven by the level of GRN expression but more probably mediated by additional modifier factors. This is also consistent with the observation that serum progranulin levels only moderately correlate with its CSF levels, and thereby may not accurately reflect progranulin regulation in the brain (Meeter et al., 2016; Nicholson et al., 2014; Wilke et al., 2016) . Hence, this study suggests that the pathophysiological cascade leading to focal neurodegeneration and phenotypical heterogeneity in FTD GRN carriers may not be fully reflected by the expression of progranulin haploinsufficiency in plasma.
Although false negative results represent only 1.9% of our series, this issue has important clinical implications. Sampling issues, technical variability or environmental factors might have transiently increased plasma progranulin levels in two carriers who had decreased levels under 71 ng/mL on follow-up samples. More strikingly, one male patient who suffered morbid obesity had normal levels at baseline as well as 20 months later. Interestingly, most other patients of this study who carried the same mutation had low plasma levels. This illustrates that progranulin expression depends not only on the presence of a given mutation, but also on external factors. For instance, dietary intake, hormonal and metabolic conditions such as insulin resistance, diabetes mellitus or obesity have been shown to increase progranulin expression (Miehle et al., 2016; Nguyen et al., 2013; Nicoletto et al., 2018; Qu et al., 2013) . Morbid obesity possibly mediated higher progranulin levels in our patient, which illustrates that caution should be taken in the interpretation of plasma progranulin levels, especially in individuals harboring specific comorbidities.
Pathophysiological mechanisms implicated in GRN-related disorders are probably even more complex, also due to the additional role of genetic modifiers that may influence progranulin expression. The protective minor G-allele of rs1990622 in TMEM106B was previously associated with reduced disease penetrance in GRN patients (Finch et al., 2011; Lattante et al., 2014; Van Deerlin et al., 2010) and increased progranulin levels in plasma (Finch et al., 2011) .
Our current results showed no association between the rs1990622 allele and plasma progranulin levels, but, among GRN carriers, those who were homozygous for the minor Gallele were found to have slightly higher plasma progranulin levels.
Finally, our study confirmed that progranulin expression in plasma predicts GRN mutation status, independently of symptoms onset proximity (Finch et al., 2009 ), but is not predictive of phenotype or age at onset. Nonetheless, the use of progranulin expression in plasma is a major breakthrough in the development of blood-based biomarkers of a brain-specific disorder. This work supports its value as an accurate screening test for individuals carrying GRN mutations, across the natural history of disease, as previously reported (Finch et al., 2009; Galimberti et al., 2018b) . Furthermore, progranulin expression in plasma can be a valuable tool to support the causative role of GRN mutations with unknown pathogenicity (Saracino et al., 2019) .
Thus, plasma progranulin levels constitute a simple, reliable and cost-effective biological marker suitable as a screening tool in clinical practice. Positive screening showing low progranulin in blood should then trigger a genetic sequencing for GRN mutations. An appropriate genetic counseling should be offered beforehand. The development of next generation sequencing facilitates molecular analyses of FTD genes especially in familial forms of bvFTD. However, GRN mutations are also responsible for 3-5% of non-familial cases (Le Ber et al., 2007) , and for a larger phenotypic spectrum including PPA and CBS.
These patients without family history or with an atypical presentation are less likely to be referred for molecular diagnosis and thus should primarily benefit from the progranulin plasma dosage. On the other hand, plasma progranulin dosage must not be proposed in clinical practice to individuals at risk of carrying GRN mutations in the context of a presymptomatic testing protocol, as their genetic status must be formally ascertained by molecular analysis. In this group, it should be limited exclusively to research settings, particularly for monitoring clinical trials based on progranulin restoring therapy.
Finally, we advocate that it could be routinely offered in clinical practice at the symptomatic stage of FTD diseases, and more broadly in the work-up of neurocognitive disorders as an aid to diagnosis. In this latter indication, further studies should be conducted to determine the diagnostic/prognostic values of plasmatic progranulin. 
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